Table 5.

Comparison of treatment and survival between patients by cytopathologic classes of repeat EUS-FNA for suspected pancreatic malignancy at St. Paul's Hospital, Vancouver, British Columbia, between 2007 and 2014.

	Repeat EUS-FNA demonstrating definite or likely adenocarcinoma (n = 10)	Repeat EUS-FNA not demonstrating definite or likely adenocarcinoma (n = 35)	P value
Offered treatment, n (%)	4/10 (40%)	12/35 (34%)	0.73
One-year survival, n (%)	6/10 (60%)	27/35 (77%)	0.42
Two-year survival, n (%)+	1/9 (11%)	19/33 (56%)	0.02∗

Treatment and survival and one and two years among 45 patients with suspected pancreatic cancer who underwent repeat EUS-FNA (EUS-FNA: endoscopic ultrasound fine-needle aspiration; SD: standard deviation; ∗ indicates statistical significance, P < 0.05; + calculated only for 42/45 patients recruited into the study prior to May 2013.).